ZBIOZenas BioPharma, Inc.
$27.24+44% 1Y
$27.24
$15.2052 weeks$43.17
The financials
Zenas BioPharma, Inc. by the numbers
Zenas BioPharma, Inc. (ZBIO) reported revenue of $1.0M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $111M. For the full year FY2025, revenue was $10M (+100% year on year) and net income −$378M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.0M | $0 | n/a |
| Operating income | −$108M | −$55M | n/a |
| Net income | −$111M | −$52M | n/a |
| Diluted EPS | −$1.77 | −$1.25 | n/a |
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry